Matches in SemOpenAlex for { <https://semopenalex.org/work/W4368341716> ?p ?o ?g. }
- W4368341716 endingPage "25" @default.
- W4368341716 startingPage "15" @default.
- W4368341716 abstract "Neovascular eye diseases include conditions such as retinopathy of prematurity, proliferative diabetic retinopathy, and neovascular age-related macular degeneration. Together, they are a major cause of vision loss and blindness worldwide. The current therapeutic mainstay for these diseases is intravitreal injections of biologics targeting vascular endothelial growth factor (VEGF) signaling. Lack of universal response to these anti-VEGF agents coupled with the challenging delivery method underscore a need for new therapeutic targets and agents. In particular, proteins that mediate both inflammatory and proangiogenic signaling are appealing targets for new therapeutic development. Here, we review agents currently in clinical trials and highlight some promising targets in preclinical and early clinical development, focusing on the redox-regulatory transcriptional activator APE1/Ref-1, the bioactive lipid modulator soluble epoxide hydrolase, the transcription factor RUNX1, and others. Small molecules targeting each of these proteins show promise for blocking neovascularization and inflammation. The affected signaling pathways illustrate the potential of new antiangiogenic strategies for posterior ocular disease. SIGNIFICANCE STATEMENT: Discovery and therapeutic targeting of new angiogenesis mediators is necessary to improve treatment of blinding eye diseases like retinopathy of prematurity, diabetic retinopathy, and neovascular age-related macular degeneration. Novel targets undergoing evaluation and drug discovery work include proteins important for both angiogenesis and inflammation signaling, including APE1/Ref-1, soluble epoxide hydrolase, RUNX1, and others." @default.
- W4368341716 created "2023-05-05" @default.
- W4368341716 creator A5005073779 @default.
- W4368341716 creator A5011277502 @default.
- W4368341716 creator A5024540410 @default.
- W4368341716 creator A5052641161 @default.
- W4368341716 creator A5066401817 @default.
- W4368341716 creator A5077304115 @default.
- W4368341716 date "2023-05-04" @default.
- W4368341716 modified "2023-09-30" @default.
- W4368341716 title "Beyond VEGF: Targeting Inflammation and Other Pathways for Treatment of Retinal Disease" @default.
- W4368341716 cites W1502240334 @default.
- W4368341716 cites W1538850399 @default.
- W4368341716 cites W1802218256 @default.
- W4368341716 cites W180765966 @default.
- W4368341716 cites W1862480368 @default.
- W4368341716 cites W1947291511 @default.
- W4368341716 cites W1965311748 @default.
- W4368341716 cites W1970240314 @default.
- W4368341716 cites W1975615201 @default.
- W4368341716 cites W1977327764 @default.
- W4368341716 cites W1980228623 @default.
- W4368341716 cites W1985608223 @default.
- W4368341716 cites W1987024877 @default.
- W4368341716 cites W1987456989 @default.
- W4368341716 cites W1987725511 @default.
- W4368341716 cites W1993823773 @default.
- W4368341716 cites W1998100932 @default.
- W4368341716 cites W1998719368 @default.
- W4368341716 cites W1999449262 @default.
- W4368341716 cites W2003601423 @default.
- W4368341716 cites W2004313693 @default.
- W4368341716 cites W2008210766 @default.
- W4368341716 cites W2012107032 @default.
- W4368341716 cites W2022704784 @default.
- W4368341716 cites W2030824198 @default.
- W4368341716 cites W2033810907 @default.
- W4368341716 cites W2034060753 @default.
- W4368341716 cites W2037549456 @default.
- W4368341716 cites W2038222125 @default.
- W4368341716 cites W2041366421 @default.
- W4368341716 cites W2049953507 @default.
- W4368341716 cites W2050414506 @default.
- W4368341716 cites W2051447459 @default.
- W4368341716 cites W2052908721 @default.
- W4368341716 cites W2057722826 @default.
- W4368341716 cites W2061608251 @default.
- W4368341716 cites W2063028754 @default.
- W4368341716 cites W2068728784 @default.
- W4368341716 cites W2070686757 @default.
- W4368341716 cites W2075634939 @default.
- W4368341716 cites W2079713841 @default.
- W4368341716 cites W2081888691 @default.
- W4368341716 cites W2090557473 @default.
- W4368341716 cites W2091471291 @default.
- W4368341716 cites W2093135493 @default.
- W4368341716 cites W2095251825 @default.
- W4368341716 cites W2100299115 @default.
- W4368341716 cites W2103166794 @default.
- W4368341716 cites W2103762420 @default.
- W4368341716 cites W2112628603 @default.
- W4368341716 cites W2121883986 @default.
- W4368341716 cites W2126467871 @default.
- W4368341716 cites W2127462527 @default.
- W4368341716 cites W2128553106 @default.
- W4368341716 cites W2138480916 @default.
- W4368341716 cites W2143308131 @default.
- W4368341716 cites W2145923696 @default.
- W4368341716 cites W2147219401 @default.
- W4368341716 cites W2160226180 @default.
- W4368341716 cites W2180927634 @default.
- W4368341716 cites W2199100869 @default.
- W4368341716 cites W2406331107 @default.
- W4368341716 cites W2408091207 @default.
- W4368341716 cites W2412434883 @default.
- W4368341716 cites W2416235575 @default.
- W4368341716 cites W2430555277 @default.
- W4368341716 cites W2470703818 @default.
- W4368341716 cites W2562397748 @default.
- W4368341716 cites W2604188130 @default.
- W4368341716 cites W2605278733 @default.
- W4368341716 cites W2605465496 @default.
- W4368341716 cites W2610204288 @default.
- W4368341716 cites W2616356421 @default.
- W4368341716 cites W2618969102 @default.
- W4368341716 cites W2622377758 @default.
- W4368341716 cites W2749744642 @default.
- W4368341716 cites W2749812557 @default.
- W4368341716 cites W2754409727 @default.
- W4368341716 cites W2758767181 @default.
- W4368341716 cites W2766315223 @default.
- W4368341716 cites W2766602108 @default.
- W4368341716 cites W2773480014 @default.
- W4368341716 cites W2773483692 @default.
- W4368341716 cites W2773684309 @default.
- W4368341716 cites W2793401320 @default.
- W4368341716 cites W2794084157 @default.
- W4368341716 cites W2794100172 @default.